ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2149 • ACR Convergence 2022

    Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register

    Francisca Guimarães1, Maria Pontes-Ferreira1, Catarina Soares1, Hugo Parente2, Carolina Ochôa Matos3, Roberto Costa3, Daniela Oliveira4, Catarina Abreu5, Rafaela teixeira6, Sofia Ferreira Azevedo7, João Madruga-Dias8, Filipe Araújo9, Carla Campinho Ferreira10, Daniela Santos-Faria2 and José Tavares-Costa2, 1Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, 2Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, 3Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 4Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal, 5Rheumatology Department, Hospital Garcia de Orta, Lisboa, Portugal, 6Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, 7Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 8Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, 9Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, 10Rheumatology Department, Hospital de Braga, Braga, Portugal

    Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…
  • Abstract Number: 2157 • ACR Convergence 2022

    Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort

    Sophie Liem1, Saad Ahmed2, Tom Huizinga3, Thea Vliet Vlieland4, Sytske Anne Bergstra1 and Jeska de Vries-Bouwstra3, 1LUMC, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Functional disability in patients with systemic sclerosis (SSc) greatly influences quality of life. In SSc, the goal of treatment is to decrease disease burden…
  • Abstract Number: 2154 • ACR Convergence 2022

    An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

    Elizabeth Bundschuh1, Rebecca Fine2, Miruna Carnaru3, Sanchit Kumar4, Francis Perry Wilson2, Alyssa Williams1, Shannon Teaw4, Ian Odell4 and Monique Hinchcliff5, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Hartford Healthcare Medical Group, Rocky Hill, CT, 4Yale University School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
  • Abstract Number: 2146 • ACR Convergence 2022

    Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

    Philip J Mease1, Rodrigo Luppino Assad2, Shigeyoshi Tsuji3, Pascal Richette4, Arathi Setty5, Erin McDearmon-Blondell6, Tianming Gao5, Sandra Ciecinski6 and Filip Van den bosch7, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, 3Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 4Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

    Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
  • Abstract Number: 2131 • ACR Convergence 2022

    Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

    Alen Zabotti1, Sarah Ohrndorf2, William Tillett3, Marlies Neuhold4, Michel van Speybroeck5, Elke Theander6, Christine Contré7, Mohamed Sharaf8, May Shawi9, Michelle Perate10, Alexa Kollmeier11 and Pascal Richette12, 1Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Janssen Pharmaceutica, Beerse, Belgium, 6Janssen Cilag, Lund, Sweden, 7Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 8Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 9Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 10Janssen Scientific Affairs, LLC, Horsham, PA, 11Janssen-Cilag, Research & Development, LLC, San Diego, CA, 12Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
  • Abstract Number: 2158 • ACR Convergence 2022

    A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort

    Sophie Liem1, Saad Ahmed2, Jacopo Ciaffi3, Liesbeth Beaart-van de Voorde4, Anne Schouffoer5, J Geelhoed6, Nina Ajmone Marsan7, Tom Huizinga8 and Jeska de Vries-Bouwstra8, 1LUMC, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3IRCCS Istituto Ortopedico Rizzoli, Bologna/Leiden University Medical Center, Bologna, Italy, 4Leiden University Medical Center, Leiden, Netherlands, 5Leiden University Medical Center/Haga Teaching Hospital, Leiden, Netherlands, 6Leiden University Medical Center, Pulmonology, Leiden, Zuid-Holland, Netherlands, 7Leiden University Medical Center, Cardiology, Leiden, Netherlands, 8Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Combined Care in Systemic Sclerosis (CCISS) is a prospective cohort of patients referred to Leiden University Medical Center for Raynaud's Phenomenon (RP), a suspicion…
  • Abstract Number: 2156 • ACR Convergence 2022

    Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study

    Yoichi Nakayama1, Ran Nakashima1, Tomohiro Handa2, Kiminobu Tanizawa2, Akihiro Ohsumi3, Mirei Shirakashi1, Ryosuke Hiwa1, Hideaki Tsuji1, Koji Kitagori1, Shuji Akizuki4, Hajime Yoshifuji5, Hiroshi date3 and Akio Morinobu5, 1Kyoto University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kyoto, Japan, 2Kyoto University Graduate School of Medicine, Department of Respiratory Medicine, Kyoto, Japan, 3Kyoto University Graduate School of Medicine, Department of Thoracic Surgery, Kyoto, Japan, 4Kyoto universtiy hospital, Kyoto City, Japan, 5Kyoto University, Kyoto, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with microangiopathy and fibrosis affecting the skin and visceral organs. Interstitial lung disease (ILD) is a…
  • Abstract Number: 2161 • ACR Convergence 2022

    Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features

    Sabína Oreská1, Hana Storkanova1, Maja Spiritovic2, Barbora Hermankova2, Michal Vrablík3, Karel Pavelka4, Jiří Vencovský5, Ladislav Šenolt5, Radim Becvar1 and Michal Tomcik1, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 33rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. In particular, involvement of the gastrointestinal tract and systemic inflammation…
  • Abstract Number: 2150 • ACR Convergence 2022

    Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

    Federica Lumetti1, Alarico Ariani2, Camilla Coccolini3, Carlo Salvarani4 and Gilda Sandri4, 1Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, 2Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, 3Università di Modena e Reggio Emilia, Modena, Italy, 4Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy

    Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
  • Abstract Number: 2053 • ACR Convergence 2022

    Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review

    Claudia Mendoza-Pinto1, Ivet Etchegaray-Morales2, Pamela Munguía-Realpozo2, David Angel Osorio-Peña2, Socorro Méndez-Martínez1 and Mario Garcia-Carrasco2, 1Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

    Background/Purpose: There is increased interest in machine learning (ML)-based prediction models in systemic lupus erythematosus (SLE). We made a systematic review of adherence in diagnostic…
  • Abstract Number: 2111 • ACR Convergence 2022

    Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

    Dafna Gladman1, Michael Starr2, Roberto Ranza3, Ana-Maria Bravo Perdomo4, Marcie Strauss5, May Shawi6, Chenglong Han7, Emmanouil Rampakakis8, Andrew Ostor9 and Philip J Mease10, 1Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 2Montreal General Hospital, Montréal, QC, Canada, 3Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, 4Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 5Medasource, Indianapolis, IN, 6Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 7Immunology, Janssen Research & Development, LLC, Spring House, PA, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9Cabrini Medical Centre, Monash University & Emeritus Research, Melbourne, Australia, 10Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…
  • Abstract Number: 2160 • ACR Convergence 2022

    The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

    Henriette Didriksen1, Øyvind Molberg2, Adi Mehta3, Suzana Jordan4, Håvard Fretheim3, Einar Gude3, Thor Ueland3, Cathrine Brunborg3, Vyacheslav Palchevskiy5, Torhild Garen3, Øyvind Midtvedt3, Arne Andreassen3, Fridtjof Lund-Johansen3, Oliver Distler4, John Belperio5 and Anna-Maria Hoffmann-Vold3, 1Oslo University Hospital, Moss, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
  • Abstract Number: 2119 • ACR Convergence 2022

    Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    M. Elaine Husni1, Philip J Mease2, Joseph Merola3, Frank Behrens4, Ennio Giulio Favalli5, Dennis McGonagle6, William Tillett7, Shigeyoshi Tsuji8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jason Coarse10, Jérémy Lambert11 and Laure Gossec12, 1Cleveland Clinic, Cleveland, OH, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 4Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 5University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 11UCB Pharma, Colombes, France, Irigny, France, 12Sorbonne Université, Paris, France

    Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
  • Abstract Number: 2056 • ACR Convergence 2022

    Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

    Takehiro Nakai1, Sho Fukui2, Takahiro Asano3, Futoshi Iwata4, Hiroki Ozawa5, Satoshi Kawaai4, Yukihiko Ikeda1, Hiromichi Tamaki1, Mitsumasa Kishimoto6, Kenichi YAMAGUCHI7 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Kyorin University Hospital, Tokyo, Japan, 3St. Luke's International Hospital, Chuo City Tokyo, Japan, 4St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 5Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, 6Kyorin University School of Medicine, Yokohama, Japan, 7St.Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
  • Abstract Number: 1937 • ACR Convergence 2022

    Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada

    Madhavi Prasad1, Michelle Batthish2, KAREN BEATTIE2 and Roberta Berard1, 1London Health Sciences Centre, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada

    Background/Purpose: Transitioning from pediatric to adult rheumatology care around age 18 is an important and often challenging period in patients' lives. Differences between adult and…
  • « Previous Page
  • 1
  • …
  • 412
  • 413
  • 414
  • 415
  • 416
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology